Study Comparing Bioavailability of Oral Formulations of Vabicaserin
Phase 1
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00541996
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
- Healthy men aged 18-50 years.
Exclusion Criteria
- Any significant disease state.
- History of drug or alcohol abuse within 1 year.
- Abnormal liver function tests.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Assess the bioavailability of four oral formulations of vabicaserin.
- Secondary Outcome Measures
Name Time Method Obtain additional safety and tolerability data for vabicaserin in healthy male subjects.